Etanercept
Treatment for Ankylosing Spondylitis
Typical Dosage: 50mg subcutaneous once weekly or 25mg twice weekly
Effectiveness
63%
Safety Score
60%
Clinical Trials
53
Participants
40K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
60
DangerousModerateSafe
Treatment Details
Dosage Range
50mg subcutaneous once weekly or 25mg twice weekly
Time to Effect
2-4 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
96%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30,000
Monitoring:$500
Side Effect Mgmt:$500
Total Annual:$31,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
0.9
Outcome-Based Costs
Cost per Responder
$45,588
Cost per Remission
$110,714
Comparison vs NSAIDs (optimized)
Cost Difference
+$30,600/year
More expensive
QALY Difference
+0.70 QALYs
Better outcomes
Dominance
No dominance
Etanercept Outcomes
for Ankylosing Spondylitis
Efficacy Outcomes
Overall Effectiveness
+63%
Response Rate
+68%
Remission Rate
+28%
Common Side Effects
Injection site reactions
+18%
Upper respiratory tract infections
+22%
Headache
+10%
Nausea
+8%
Serious infections
+2.5%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
16 completed trials for Etanercept in Ankylosing Spondylitis
Defining Remission With Etanercept in AS in Real Life Clinical Practice
NCT02202850COMPLETED
84 participants
OBSERVATIONAL
Brussels, Belgium +28 more
Started: Aug 12, 2014
Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
NCT01188655COMPLETED
89 participants
OBSERVATIONAL
Started: May 1, 2008
Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain
NCT00873730COMPLETEDPHASE4
108 participants
INTERVENTIONAL
Started: Dec 1, 2006
Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
NCT04507763COMPLETED
763 participants
OBSERVATIONAL
Baghdad, Iraq
Started: Aug 1, 2020
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
NCT02509026COMPLETEDPHASE4
210 participants
INTERVENTIONAL
Pensacola, United States +81 more
Started: Sep 24, 2015
Study Investigating Enbrel Treatment for Ankylosing Spondylitis
NCT00195416COMPLETED
526 participants
OBSERVATIONAL
Gyunggi-do, South Korea +2 more
Started: Jun 1, 2005
Extension Study Evaluating Etanercept in Ankylosing Spondylitis
NCT00410046COMPLETEDPHASE4
84 participants
INTERVENTIONAL
Fredriksberg, Denmark +15 more
Started: Dec 1, 2006
Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
NCT00544557COMPLETED
1.72K participants
OBSERVATIONAL
Berlin, Germany
Started: Oct 1, 2007
Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
NCT01934933COMPLETEDPHASE4
150 participants
INTERVENTIONAL
Guangzhou, China
Started: Sep 24, 2014
Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.
NCT01421303COMPLETED
80 participants
OBSERVATIONAL
Ghent, Belgium
Started: Oct 1, 2009
Study Evaluating Etanercept in Patients With Ankylosing Spondylitis
NCT00458185COMPLETEDPHASE4
40 participants
INTERVENTIONAL
Started: Aug 1, 2006
16.0040 Ankylosing Spondylitis Study
NCT00356356COMPLETEDPHASE3
257 participants
INTERVENTIONAL
Started: Apr 1, 2002
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
NCT00421980COMPLETEDPHASE3
84 participants
INTERVENTIONAL
Ghent, Belgium
Started: Jun 1, 2002
Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study
NCT02915354COMPLETEDPHASE4
35 participants
INTERVENTIONAL
Guangzhou, China
Started: Jul 1, 2007
Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing Spondylitis
NCT00418548COMPLETEDPHASE3
350 participants
INTERVENTIONAL
Started: Jun 1, 2004
An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis
NCT00444340COMPLETEDPHASE4
70 participants
INTERVENTIONAL
Started: Apr 1, 2004
Showing 20 of 53 total trials